This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.
Displaying 13 papers
Evaluation of the Pharmacokinetic Interaction between Repeated Doses of Rifapentine or Rifampin and a Single Dose of Bedaquiline in Healthy Adult Subjects
Publication: Winter H, Egizi E, Erondu N, et. al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother. 2015 Feb;59(2):1219-24. doi: 10.1
Publication: Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504.
Publication: Nuermberger EL, Rosenthal IM, Tasneen R, et. al. Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12
Publication: Dutta NK, Illei PB, Peloquin CA, et. al. Rifapentine Is Not More Active than Rifampin against Chronic Tuberculosis in Guinea Pigs. http://aac.asm.org/content/56/7/3726.long. Accessed March 7, 2016
Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis
Publication: Williams K, Minkowski A, Amoabeng O, et. al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12.
Publication: Ginsberg AM, Drugs in development for tuberculosis. Drugs. 2010 Dec 3;70(17):2201-14. doi: 10.2165/11538170-000000000-00000.
Publication: Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9.
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis
Publication: Rosenthal IM, Tasneen R, Peloquin CA, et. al. Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2012 Aug; 56(8): 4331–4340. doi: 10.1128/AAC.00912-12
Publication: Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med. 2008 Oct;29(5):552-9. doi: 10.1055/s-0028-1085706.
Publication: Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008 Mar;88(2):85-6. doi: 10.1016/S1472-9792(08)70002-7.
Publication: Spigelman MK New tuberculosis therapeutics: a growing pipeline. J Infect Dis. 2007 Aug 15;196 Suppl 1:S28-34. http://jid.oxfordjournals.org/content/196/Supplement_1/S28.long. Accessed March 7, 2016
Publication: Ma Z, Ginsberg A, Spigelman M. Antimycobacterium Agents. Elsevier, Philadelphia, PA. 2007 Jan; 700-4, 719-20, 26.
Publication: O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med. 2005 Jun;26(2):327-40, vii. http://www.sciencedirect.com/science/article/pii/S0272523105000158. Accessed March 7, 2016